Ziftomenib has received Breakthrough Therapy, Fast Track, and Orphan Drug Designations. The FDA has a 60-day filing review period to determine whether the NDA is complete and accepted for review; Kura ...

Kura Oncology (KURA) announced Kura submitted a New Drug Application for ziftomenib, a highly selective, once-daily, oral, investigational ...